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Drugs represent the primary treatment available for human malaria, as caused by
Plasmodium spp. Currently approved drugs and antimalarial drug leads generally work
against parasite enzymes or activities within infected erythrocytes. To reach their specific
targets, these chemicals must cross at least three membranes beginning with the host
cell membrane. Uptake at each membrane may involve partitioning and diffusion through
the lipid bilayer or facilitated transport through channels or carriers. Here, we review the
features of available antimalarials and examine whether transporters may be required
for their uptake. Our computational analysis suggests that most antimalarials have high
intrinsic membrane permeability, obviating the need for uptake via transporters; a subset
of compounds appear to require facilitated uptake. We also review parasite and host
transporters that may contribute to drug uptake. Broad permeability channels at the
erythrocyte and parasitophorous vacuolar membranes of infected cells relax permeability
constraints on antimalarial drug design; however, this uptake mechanism is prone to
acquired resistance as the parasite may alter channel activity to reduce drug uptake. A
better understanding of how antimalarial drugs reach their intracellular targets is critical
to prioritizing drug leads for antimalarial development and may reveal new targets for
therapeutic intervention.
Keywords: antimalarials, drug uptake, plasmodial surface anion channel, plasmodium falciparum, drug absorption,
lipid diffusion of drugs
Introduction
Malaria remains a leading infectious cause of morbidity and mortality worldwide. Because an
effective vaccine is not available, treatment with drugs or drug combinations remains the mainstay
of malaria control (Visser et al., 2014). With primaquine as a notable exception (Vale et al., 2009),
the available drugs work primarily against bloodstream parasite stages, which invade and replicate
within human erythrocytes. Development within erythrocytes protects the pathogen from host
immune responses (Hafalla et al., 2011), but limits parasite access to nutrients and other solutes
in plasma (Homewood and Neame, 1974; Kutner et al., 1982; Desai et al., 2000; Staines et al., 2007).
Antimalarial drugs have focused on these bloodstream parasites because these stages are responsible
for nearly all the clinical sequelae of malaria. To be effective, the drugmust reach appropriate plasma
levels, enter the infected cell and access its intracellular target, inhibit one or more essential parasite
activities selectively, and produce rapid killing. To be useful in the developing world and to impact
global health (Burrows et al., 2013), there are a number of additional constraints on antimalarial
drugs: (1) they must be affordable, ideally costing less than $0.25 USD for a single treatment
course, (2) the drug or drug combination should cure infection without leading to dormant forms
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that yield recurrent illness or “recrudescence” (White, 2008), (3)
the risk of acquired parasite resistance must be low, (4) the drug
should be safe and nontoxic in children and pregnant women,
groups prone tomore severemalaria, (5) the drug should be effec-
tive against multiple parasite species, ideally preventing relapses
associated with P. vivax and P. ovale, (6) the drug should be
effective in both acute therapy and prophylaxis, as needed by
travelers to endemic areas, (7) the formulation should be sta-
ble and distributed easily without refrigeration or other precau-
tions, (8) oral administration of ideally a single curative dose is
strongly preferred, and (9) pharmacokinetic properties such as
half-life and route of excretion should be optimized to ensure
cure, but avoid development of parasite resistance. This long list of
desired attributes has thwarted drug discovery and development
in malaria, accounting for the limited number of approved drugs
available for treatment of this important disease.
In light of thesemajor hurdles, the precisemechanismof action,
access to the parasite target, and possible resistance mechanisms
are oftennot explored as extensively asmight otherwise be desired.
Here, we consider the fundamental question of how drugs reach
their parasite target. Nearly all antimalarials must cross multiple
membrane barriers to reach their parasite target within infected
erythrocytes. We report that most approved drugs and drug leads
have chemical properties that allow free diffusion through lipid
bilayers to reach their intracellular targets; transporters at specific
membranes also contribute to uptake of more hydrophilic agents.
Two Mechanisms of Drug Uptake by Cells
Small organic solutes such as nutrients and drugs enter cells by
crossing the surface membrane, which is made of phospholipids,
cholesterol, and other amphipathic molecules arranged in a 50
Å bilayer. Biological membranes also contain embedded proteins
that may function as receptors and solute transporters. Thus,
nutrients and drugs may cross the membrane either by diffu-
sion through the lipid bilayer portion or by use of a carrier or
transporter protein, a process commonly referred to as facilitated
diffusion or active transport if external energy is used in the
transport cycle. Historically, lipid-based diffusion was thought to
be the main route for uptake of drugs, but with the identification
of organic solute carriers (Hediger et al., 2004; Dobson and Kell,
2008), facilitated diffusion has become increasingly appreciated.
Certainly, these mechanisms may coexist, depending on the cell
type and the specific drug in question (Sugano et al., 2010).
A few characteristics of these two mechanisms may help deter-
mine which route is dominant for a given drug. Lipid-based
diffusion is generally restricted to uncharged chemicals or drugs
because charged solutes do not partition easily into the lipid
core of a membrane bilayer. Because specific binding sites are
not involved, lipid-based diffusion is generally not saturable, not
subject to inhibition, and not sensitive to drug stereospecificity.
Although there are cell-specific differences in lipid composition
and bilayer structure, the physicochemical properties of biological
membranes are largely conserved; as a result, lipid-based diffusion
of a drug generally does not vary between cell types. In con-
trast, carrier-mediated uptake is typically saturable, amenable to
pharmacological inhibition, and affected by drug stereospecificity.
Because expression of solute carriers is specific to certain cell
types and differs amongst higher organisms, drug uptake by this
mechanism may vary dramatically from cell to cell. Both mech-
anisms allow movement of a drug by mass action, i.e., down its
concentration gradient, but some carriers can transport solutes
against their concentration gradient by coupling movement to
ATP hydrolysis or the flux of another solute.
While carrier-mediated uptake cannot be readily predicted by
knowledge of the physical and chemical properties of a drug,
significant effort has been invested in predicting lipid-based dif-
fusion of drugs. Because lipid diffusion correlates with passive
intestinal absorption, ensuring adequate permeability by this
mechanism is particularly important during the drug discovery
and development process. Compounds with high lipid diffusion
are more likely to be orally absorbed and to reach therapeutic lev-
els at their target site. One approach has been to use in vitro assays
such as the Caco-2 intestinal cell permeability assay and the paral-
lel artificial membrane permeability assay, PAMPA (Kansy et al.,
2004; van Breemen and Li, 2005). Since their introduction, these
assays have helped reduce drug development program failures
by revealing poor pharmacokinetic properties at an early stage.
Nevertheless, these assays exhibit significant lab-to-lab variability
and remain imperfect predictors of oral absorption in animals.
Another important approach to predicting lipid diffusion has
involved computational methods that consider the physicochem-
ical properties of drugmolecules. One widely recognized example
is the Lipinski’s “Rule of 5,” which examined a large collection of
late stage drug candidates with established oral bioavailability to
identify simple parameters that predict passive intestinal absorp-
tion (Lipinski et al., 2001). They defined threshold values of four
parameters—calculated LogP (CLogP), molecular weight, num-
ber of H-bond donors, and number of H-bond acceptors—that
predicted good oral absorption. A limitation of this approach
is that it does not quantify the degree of lipid permeability of
well-absorbed compounds; it also leaves many compounds in an
uncertain category as they satisfy some but not all of the criteria.
Thus, a number of increasingly complex algorithms have been
developed (Camenisch et al., 1998; Zhao et al., 2002; Yan et al.,
2008). An important problem with these algorithms is that the
parameters used—polar surface area (PSA), polarizability, various
measures of lipophilicity (logP, log D, non-PSA, etc.), molecu-
lar volume, and other parameters used in the Lipinski Rule of
5—are interrelated, so the relative importance of each parameter
is unclear.
Another problem is that calculation or measurement of some
parameters is not readily available to all workers, especially
those in academia. Commercial software is available to calculate
these parameters and estimates oral bioavailability, distribution
in mammalian organs, metabolism, and excretion; however, such
software is expensive and typically available only to workers in the
pharmaceutical sector.
Predicted Lipid Permeability of
Antimalarials
To explore whether existing antimalarials use lipid-based or
carrier-mediated uptake to reach their intracellular targets, we
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FIGURE 1 | Routes used by antimalarial compounds to reach their
intracellular parasite targets. (A) Plot of PSA vs. AlogP98 for antimalarial
compounds, calculated using Accelrys Draw 4.2. Solid lines represent the
95 and 99% confidence ellipses for drugs with good absorption (inner and outer
ellipses, respectively), as determined by (Egan et al., 2000). Notice that approved
antimalarial drugs generally fall within these ellipses (green circles), indicating
a high likelihood for adequate lipid-diffusion to reach intracellular targets.
Compounds in the medicines for malaria (MMV) pipeline and key antimalarial
toxins are shown as blue triangles and red squares, respectively. Approved
drugs shown: chloroquine, mefloquine, quinine, artemisinin, dihydroartemisinin,
artesunate, artemether, atovaquone, proguanil, naphthoquine, amodiaquine,
piperaquine, doxycycline**, clindamycin, azithromycin**, sulfadoxine,
lumefantrine**, pyrimethamine, pyronaridine. MMV pipeline compounds:
DSM265, MMV390048, NITD609, KAF156, P218*, SJ733, PA21A092,
OZ439, tafenoquine. Antimalarial toxins: fosmidomycin*, blasticidin S**,
leupeptin**, pentamidine. Single asterisk indicates compound is outside the 95%
confidence ellipse only; Double asterisk indicates compound is outside both
ellipses. (B) Schematic showing membrane barriers and transporters available
for drug uptake at key membranes of the infected erythrocyte. Drugs may
enter via lipid-diffusion (upper arrows) or through PSAC or a host transporter
(e.g., organic anion transporter, OAT) at the erythrocyte membrane, the PVM
channel at the parasitophorous vacuolar membrane (PVM), and one or more
transporters (e.g., aquaglyceroporin, AQP) at the parasite plasma membrane
(PPM). Drugs may act within parasite organelles such as the digestive
vacuole (DV, shown containing crystalline hemozoin) or the multilamellar
apicoplast (Ap), imposing additional membranous barriers; drug transporters
are also present at these membranes (not shown). A parasite-generated
Maurer’s cleft (MC) is shown in the host cytosol. Transporters for nutrients such
as sugars, amino acids, and nucleobases are also present at some membranes
(not shown); certain drugs may use these nutrient transporters for uptake.
used a computational approach that overcomes some of these
limitations. The multivariate approach developed by Egan et al.
(2000) identified AlogP98, a computationally simpler method
of estimating logP values (Ghose et al., 1998), and PSA as two
independent parameters that contribute to lipid-based diffusion
(Egan et al., 2000). They then defined ranges of these values
that correlated with absorption by examining collections of well-
absorbed and poorly-absorbed drugs.Well-absorbed drugs repro-
ducibly exhibited values for these parameters that fell within an
ellipse in a two-dimensional plot; Figure 1A shows the 95 and
99% confidence ellipses for well-absorbed drugs taken from their
analyses (areas encoded by the inner and outer solid curves,
respectively). Compounds from their poorly-absorbed collection
were consistently outside of these ellipses, with only 1 compound
lying just within their 95% ellipse.
We then calculated AlogP98 and PSA for approved antimalarial
drugs, drug leads and compounds in the Medicines for Malaria
pipeline (Burrows et al., 2013), and other antimalarial agents of
interest. These values were added to Figure 1A, using distinct
symbols for each class of compounds. Notably, most of the com-
pounds fall within the good absorption 95% confidence ellipse,
a finding consistent with the need to cross multiple membranes
to reach their intracellular parasite drug targets (Figure 1B, dis-
cussed in detail below).Without good absorption at thesemultiple
membranes, a compound is not likely to interfere with parasite
propagation under either in vitro or in vivo conditions.
Figure 1A shows that three approved antimalarials and 4 drug
leads are predicted to have marginal or poor absorption (sym-
bols outside of the inner ellipse). How do these compounds
reach their intracellular targets to produce parasite killing? As
discussed below, three of these compounds, blasticidin S, leu-
peptin, and fosmidomycin, cross the host erythrocyte mem-
brane through a parasite-induced channel (Hill et al., 2007; Lisk
et al., 2008, 2010; Baumeister et al., 2011; Nair et al., 2011).
Three approved antimalarial drugs, doxycycline, azithromycin,
and lumefantrine, are predicted to be poorly absorbed (filled
circles outside outer ellipse, Figure 1A), but their uptake by
infected cells has not been directly studied; each has known
problems with oral absorption, with facilitated or active trans-
port already established for some cell types (Meshali and Attia,
1978; Farmer et al., 1992; Ezzet et al., 2000; Wahajuddin et al.,
2014). Finally, the preclinical antimalarial candidate P218 falls
just outside the inner ellipse; because it is reported to have
good oral bioavailability (Yuthavong et al., 2012), this com-
pound may also use facilitated transport on carriers or chan-
nels.
At Least Three Membranes to be Crossed
Antimalarials with targets within the intracellular parasite must
sequentially traverse three membranes by lipid diffusion, flux
through one ormore transporters, or bothmechanisms in parallel
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(Figure 1B). The solute transport properties of these membranes
are reviewed next.
The Host Erythrocyte Membrane
In addition to organic solute carriers endogenous to human ery-
throcytes (Figure 1B, OAT; Heijn et al., 1992; Saxena and Hen-
derson, 1996; Zipprer et al., 2014), an unusual ion and nutrient
channel known as the plasmodial surface anion channel (PSAC)
is induced on the host membrane of infected cells to increase ion
and organic solute permeabilities (Overman, 1948; Ginsburg et al.,
1983; Desai et al., 2000). PSAC activity has recently been linked
to the parasite clag gene family (Nguitragool et al., 2011). Solutes
transported by this channelmay be charged or uncharged andmay
have molecular weights over 600 dal (Cohn et al., 2003), suggest-
ing that this route may be accessible to many drugs. Remarkably,
the small Na+ ion is excluded by poorly understood mechanisms,
though uptake studies at basic pH values suggest a contribution of
electrostatic repulsion (Cohn et al., 2003). Although the channel
functions primarily in uptake of essential nutrients (Pillai et al.,
2012, 2013), a number of drugs or drug leads also have demon-
strated uptake via this channel (Stead et al., 2001; Biagini et al.,
2003; Hill et al., 2007; Lisk et al., 2008, 2010; Baumeister et al.,
2011; Dana et al., 2014). Blasticidin S and leupeptin, two agents
that require PSAC-mediated uptake, have been used to select
transport mutants and provide molecular insights into solute
transport by this channel (Mira-Martinez et al., 2013; Sharma
et al., 2013). These transport mutants preserve uptake of essential
nutrients, but produce resistance by reducing uptake of the toxin
selectively. They also support an essential role of PSAC because
complete loss-of-function mutants have not been generated in
vitro or identified in ex vivo samples (Desai, 2012).
Plasmodial surface anion channel or other parasite-associated
channels may contribute to uptake of existing antimalarial drugs
such as artemisinin (Vyas et al., 2002; Duranton et al., 2005).
With evolving guidelines for the design of antimalarials with
greater water solubility (Burrows et al., 2013), future drugs may
depend on PSAC-mediated uptake to a greater extent. An impor-
tant concern is whether resistance and clinical failures may arise
quickly through the selection of PSAC mutants. The availabil-
ity of potent and specific PSAC inhibitors permits easy deter-
mination of whether a drug requires channel-mediated uptake
(Pillai et al., 2010), using either radiolabeled drug uptake or in
vitro growth inhibition studies in combination experiments with
PSAC inhibitors (Lisk et al., 2010). Given the risk of acquired
drug resistance through reduced uptake, drug discovery programs
should routinely test their lead compounds for uptake via this
channel.
The Parasitophorous Vacuolar Membrane
Drugs that have entered the erythrocyte cytosol then encounter
the parasitophorous vacuolar membrane (PVM), which sur-
rounds the parasite throughout its intracellular cycle. Because
the PVM is closely apposed to the underlying parasite plasma
membrane (Figure 1B), its transport properties have been rela-
tively difficult to characterize. Patch-clamp studies have however,
revealed a single large conductance ion channel at the PVM (Desai
et al., 1993). Present at high density on this membrane, this
channel mediates the high capacity transport of both cations and
anions; inorganic and organic ions including tris+, lysine+, and
glucuronate- are transported with indistinguishable rates. Subse-
quent reconstitution into planar lipid bilayers yielded a size cut-off
of 1400 dal for permeating solutes (Desai and Rosenberg, 1997).
Consistent with these electrophysiological studies, biochemical
measurements also suggest free exchange of large organic solutes
at the PVM (Nyalwidhe et al., 2002). Although themolecular basis
of this channel remains unknown, it appears to be highly con-
served in apicomplexan parasites, with similar activity observed in
Toxoplasma gondii (Schwab et al., 1994). These transport features
suggest that most, if not all, antimalarial drugs will readily cross
the PVM through this channel. The PVMchannel does not appear
to be inhibited by high concentrations of quinine, chloroquine or
artemisinin, suggesting that it may also be an unexplored drug
target (Desai and Rosenberg, 1997).
A recently identified plasmodium translocon of exported pro-
teins (PTEX) is also found at the PVM (Goldberg and Cowman,
2010). PTEX functions to export many parasite proteins to the
host cytosol (Beck et al., 2014; Elsworth et al., 2014), enabling a
dramatic remodeling of the erythrocyte. Because protein translo-
cons in other organisms allow ion flux (Simon and Blobel, 1991,
1992), one possibility is that PVM channel and PTEX activities are
mediated by the same molecular complex.
The Parasite Plasma Membrane
Drug transport at the third membranous barrier, the parasite
plasma membrane (Figure 1B), is poorly understood. Although
a number of transporters and pumps have been identified at
this membrane through either biochemical studies of freed par-
asites or through computational approaches that search for
orthologs of known solute transporters (Woodrow et al., 1999;
Rager et al., 2001), most known transporters at this mem-
brane are thought to have restricted substrate specificities and
may not mediate drug uptake. A possible exception is a para-
site aquaglyceroporin, PfAQP, at the parasite plasma membrane
(Hansen et al., 2002). This atypical water channel transports glyc-
erol, sugar alcohols with up to five carbons and various toxic
compounds containing carbonyl groups (Pavlovic-Djuranovic
et al., 2006; Zeuthen et al., 2006). A subset of antimalarial
agents may therefore access parasite cytosol via this promiscu-
ous channel, as has also been reported in Trypanosoma brucei
(Munday et al., 2014).
Further evidence for limited permeability of the parasite plasma
membrane comes from studies with fosmidomycin, a drug lead
with poor lipid-based uptake (Figure 1A). This agent targets iso-
prenoid biosynthesis in the parasite apicoplast, but is surprisingly
inactive against related parasites such as Toxoplasma gondii that
also depend on this biosynthetic pathway. A recent study trans-
fected T. gondii parasites with a bacterial glycerol-3-phosphate
transporter and targeted it for the parasite plasma membrane
(Nair et al., 2011). Interestingly, expression of this transporter
allowed fosmidomycin uptake and conferred a>100-fold increase
in drug action against that parasite. It is unclear how fos-
midomycin and other poorly permeable drug leads such as blasti-
cidin S, leupeptin, and doxycycline (Figure 1A) cross the parasite
plasma membrane in malaria parasites, but drug conjugation
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with the permeability-promoting octaarginine peptide suggests
that this membrane may be a limiting barrier in malaria parasites
also (Sparr et al., 2013). These agents and other drugs may cross
the parasite plasma membrane on one of several nutrient carriers
that have been localized to this membrane (Woodrow et al., 1999;
Carter et al., 2000)
Many drugs act against targets with parasite organelles and
must therefore cross one or more additional membranes after
uptake at the parasite plasma membrane. For example, a number
of drugs including chloroquine andmefloquine act in the parasite
digestive vacuole and must cross this organelle’s membrane to
be effective. Two intensively studied transporters, PfCRT and
PfMDR1 (also known as Pgh-1), localize to this membrane and
carry mutations or copy number variations confering resistance
to various antimalarials (Duraisingh and Cowman, 2005; Sa et al.,
2009). These altered transporters may confer resistance by pump-
ing drugs out of the vacuole, confirming the clinical relevance of
drug permeability considerations.
Conclusion
Because the targets of most antimalarial drugs and drug leads
are proteins within the intracellular bloodstream parasite, these
compounds must cross at least three membranes to effect parasite
killing. They may cross each of these membranous barriers by
either lipid-diffusion or by use of one or more transporters of
host or parasite origin. Our analysis shows that most existing
antimalarials have physicochemical properties consistent with
lipid-diffusion at rates sufficient for oral uptake and accumulation
within the infected erythrocytes. Broad selectivity ion channels
at the host plasma membrane and the PVM provide a route for
diverse antimalarials thatmight not readily enter other cells.Many
existing antimalarial drugs will then also need to cross additional
membranes within the parasite to reach their specific targets
parasite organelles such as the digestive vacuole. Transporters
and channels that facilitate drug uptake by infected cells have
been identified and are under active study. Together with new
approaches to estimate lipid-diffusion of drugs, a clear under-
standing of how drugs reach their parasite targets is now possible.
This understanding will help prioritize drug leads, improve ther-
apeutic algorithms with drug combinations, and provide critical
insights into drug resistance mechanisms.
Acknowledgments
This research was supported by the Intramural Research Pro-
gram of the National Institutes of Health, National Institute of
Allergy and Infectious Diseases andMicrobiotix, Inc., which has a
cooperative research and development agreement (CRADA) with
NIAID.
References
Baumeister, S., Wiesner, J., Reichenberg, A., Hintz, M., Bietz, S., Harb, O. S., et al.
(2011). Fosmidomycin uptake into plasmodium and babesia-infected erythro-
cytes is facilitated by parasite-induced new permeability pathways. PLoS ONE
6:e19334. doi: 10.1371/journal.pone.0019334
Beck, J. R., Muralidharan, V., Oksman, A., and Goldberg, D. E. (2014). PTEX
component HSP101 mediates export of diverse malaria effectors into host
erythrocytes. Nature 511, 592–595. doi: 10.1038/nature13574
Biagini, G. A., Richier, E., Bray, P. G., Calas, M., Vial, H., and Ward, S. A. (2003).
Heme binding contributes to antimalarial activity of bis-quaternary ammoni-
ums. Antimicrob. Agents Chemother. 47, 2584–2589. doi: 10.1128/AAC.47.8.
2584-2589.2003
Burrows, J. N., van Huijsduijnen, R. H., Mohrle, J. J., Oeuvray, C., and Wells, T.
N. (2013). Designing the next generation of medicines for malaria control and
eradication.Malar. J. 12, 187. doi: 10.1186/1475-2875-12-187
Camenisch, G., Alsenz, J., van de Waterbeemd, H., and Folkers, G. (1998). Estima-
tion of permeability by passive diffusion through Caco-2 cell monolayers using
the drugs’ lipophilicity andmolecular weight. Eur. J. Pharm. Sci. 6, 317–324. doi:
10.1016/S0928-0987(97)10019-7
Carter, N. S., BenMamoun, C., Liu,W., Silva, E. O., Landfear, S. M., Goldberg, D. E.,
et al. (2000). Isolation and functional characterization of the PfNT1 nucleoside
transporter gene from Plasmodium falciparum. J. Biol. Chem. 275, 10683–10691.
doi: 10.1074/jbc.275.14.10683
Cohn, J. V., Alkhalil, A., Wagner, M. A., Rajapandi, T., and Desai, S. A. (2003).
Extracellular lysines on the plasmodial surface anion channel involved in
Na+ exclusion.Mol. Biochem. Parasitol. 132, 27–34. doi: 10.1016/j.molbiopara.
2003.08.001
Dana, S., Prusty, D., Dhayal, D., Gupta, M. K., Dar, A., Sen, S., et al. (2014).
Potent antimalarial activity of acriflavine in vitro and in vivo. ACS Chem. Biol. 9,
2366–2373. doi: 10.1021/cb500476q
Desai, S. A. (2012). Ion and nutrient uptake by malaria parasite-infected erythro-
cytes. Cell. Microbiol. 14, 1003–1009. doi: 10.1111/j.1462-5822.2012.01790.x
Desai, S. A., Bezrukov, S. M., and Zimmerberg, J. (2000). A voltage-dependent
channel involved in nutrient uptake by red blood cells infected with the malaria
parasite. Nature 406, 1001–1005. doi: 10.1038/35023000
Desai, S. A., Krogstad, D. J., and McCleskey, E. W. (1993). A nutrient-permeable
channel on the intraerythrocytic malaria parasite. Nature 362, 643–646. doi:
10.1038/362643a0
Desai, S. A., and Rosenberg, R. L. (1997). Pore size of the malaria parasite’s nutrient
channel. Proc. Natl. Acad. Sci. U.S.A. 94, 2045–2049. doi: 10.1073/pnas.94.5.2045
Dobson, P. D., and Kell, D. B. (2008). Carrier-mediated cellular uptake of pharma-
ceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205–220. doi:
10.1038/nrd2438
Duraisingh, M. T., and Cowman, A. F. (2005). Contribution of the pfmdr1
gene to antimalarial drug-resistance. Acta Trop. 94, 181–190. doi: 10.1016/
j.actatropica.2005.04.008
Duranton, C., Akkaya, C., Brand, V. B., Tanneur, V., Lang, F., and Huber, S.
M. (2005). Artemisinin inhibits cation currents in malaria-infected human
erythrocytes. Nanomedicine 1, 143–149. doi: 10.1016/j.nano.2005.03.010
Egan, W. J., Merz, K. M. Jr., and Baldwin, J. J. (2000). Prediction of drug
absorption using multivariate statistics. J. Med. Chem. 43, 3867–3877. doi:
10.1021/jm000292e
Elsworth, B., Matthews, K., Nie, C. Q., Kalanon, M., Charnaud, S. C., Sanders, P. R.,
et al. (2014). PTEX is an essential nexus for protein export in malaria parasites.
Nature 511, 587–591. doi: 10.1038/nature13555
Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S., and White, N. J. (2000).
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in
acute falciparum malaria. Antimicrob. Agents Chemother. 44, 697–704. doi:
10.1128/AAC.44.3.697-704.2000
Farmer, S., Li, Z. S., and Hancock, R. E. (1992). Influence of outer membrane
mutations on susceptibility of Escherichia coli to the dibasic macrolide
azithromycin. J. Antimicrob. Chemother. 29, 27–33. doi: 10.1093/jac/
29.1.27
Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. (1998). Prediction of
hydrophobic (Lipophilic) properties of small organic molecules using fragmen-
tal methods: an analysis of ALOGP and CLOGPmethods. J. Phys. Chem. A 102,
3762–3772. doi: 10.1021/jp980230o
Ginsburg, H., Krugliak, M., Eidelman, O., and Cabantchik, Z. I. (1983). New
permeability pathways induced in membranes of Plasmodium falciparum
infected erythrocytes. Mol. Biochem. Parasitol. 8, 177–190. doi: 10.1016/0166-
6851(83)90008-7
Frontiers in Pharmacology | www.frontiersin.org May 2015 | Volume 6 | Article 915
Basore et al. Antimalarial drug uptake by infected erythrocytes
Goldberg, D. E., and Cowman, A. F. (2010). Moving in and renovating: export-
ing proteins from Plasmodium into host erythrocytes. Nat. Rev. Microbiol. 8,
617–621. doi: 10.1038/nrmicro2420
Hafalla, J. C., Silvie, O., andMatuschewski, K. (2011). Cell biology and immunology
of malaria. Immunol. Rev. 240, 297–316. doi: 10.1111/j.1600-065X.2010.00988.x
Hansen, M., Kun, J. F., Schultz, J. E., and Beitz, E. (2002). A single, bi-functional
aquaglyceroporin in blood-stage Plasmodium falciparum malaria parasites. J.
Biol. Chem. 277, 4874–4882. doi: 10.1074/jbc.M110683200
Hediger, M. A., Romero, M. F., Peng, J. B., Rolfs, A., Takanaga, H., and Bruford,
E. A. (2004). The ABCs of solute carriers: physiological, pathological and thera-
peutic implications of humanmembrane transport proteins. Pflugers. Arch. 447,
465–468. doi: 10.1007/s00424-003-1192-y
Heijn, M., Oude Elferink, R. P., and Jansen, P. L. (1992). ATP-dependent multispe-
cific organic anion transport system in rat erythrocyte membrane vesicles. Am.
J. Physiol. 262, C104–C110.
Hill, D. A., Pillai, A. D., Nawaz, F., Hayton, K., Doan, L., Lisk, G., et al. (2007).
A blasticidin S-resistant Plasmodium falciparum mutant with a defective plas-
modial surface anion channel. Proc. Natl. Acad. Sci. U.S.A. 104, 1063–1068. doi:
10.1073/pnas.0610353104
Homewood, C. A., and Neame, K. D. (1974). Malaria and the permeability of the
host erythrocyte. Nature 252, 718–719. doi: 10.1038/252718a0
Kansy, M., Avdeef, A., and Fischer, H. (2004). Advances in screening for membrane
permeability: high-resolution PAMPA for medicinal chemists. Drug Discov.
Today Technol. 1, 349–355. doi: 10.1016/j.ddtec.2004.11.013
Kutner, S., Baruch, D., Ginsburg, H., and Cabantchik, Z. I. (1982). Alterations
in membrane permeability of malaria-infected human erythrocytes are related
to the growth stage of the parasite. Biochim. Biophys. Acta 687, 113–117. doi:
10.1016/0005-2736(82)90178-X
Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Experi-
mental and computational approaches to estimate solubility and permeability
in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26. doi:
10.1016/S0169-409X(00)00129-0
Lisk, G., Pain, M., Gluzman, I. Y., Kambhampati, S., Furuya, T., Su, X. Z., et
al. (2008). Changes in the plasmodial surface anion channel reduce leupeptin
uptake and can confer drug resistance in P. falciparum-infected erythrocytes.
Antimicrob. Agents Chemother. 52, 2346–2354. doi: 10.1128/AAC.00057-08
Lisk, G., Pain, M., Sellers, M., Gurnev, P. A., Pillai, A. D., Bezrukov, S. M.,
et al. (2010). Altered plasmodial surface anion channel activity and in vitro
resistance to permeating antimalarial compounds. Biochim. Biophys. Acta 1798,
1679–1688. doi: 10.1016/j.bbamem.2010.04.013
Meshali, M. M., and Attia, I. E. (1978). Transport mechanism of some naturally
occurring tetracyclines across everted rat gut. Pharmazie 33, 107–109.
Mira-Martinez, S., Rovira-Graells, N., Crowley, V. M., Altenhofen, L. M., Llinas,
M., and Cortes, A. (2013). Epigenetic switches in clag3 genes mediate blasticidin
S resistance in malaria parasites. Cell. Microbiol. 15, 1913–1923.
Munday, J. C., Eze, A. A., Baker, N., Glover, L., Clucas, C., Aguinaga, A. D., et al.
(2014).Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for
pentamidine and melaminophenyl arsenic drugs and the main genetic determi-
nant of resistance to these drugs. J. Antimicrob. Chemother. 69, 651–663. doi:
10.1093/jac/dkt442
Nair, S. C., Brooks, C. F., Goodman, C. D., Sturm, A., McFadden, G. I., Sundriyal, S.,
et al. (2011). Apicoplast isoprenoid precursor synthesis and the molecular basis
of fosmidomycin resistance in Toxoplasma gondii. J. Exp. Med. 208, 1547–1559.
doi: 10.1084/jem.20110039
Nguitragool, W., Bokhari, A. A., Pillai, A. D., Rayavara, K., Sharma, P.,
Turpin, B., et al. (2011). Malaria parasite clag3 genes determine channel-
mediated nutrient uptake by infected red blood cells. Cell 145, 665–677. doi:
10.1016/j.cell.2011.05.002
Nyalwidhe, J., Baumeister, S., Hibbs, A. R., Tawill, S., Papakrivos, J., Volker, U., et
al. (2002). A nonpermeant biotin derivative gains access to the parasitophorous
vacuole in Plasmodium falciparum-infected erythrocytes permeabilized with
streptolysin O. J. Biol. Chem. 277, 40005–40011. doi: 10.1074/jbc.M207077200
Overman, R. R. (1948). Reversible cellular permeability alterations in disease. In
vivo studies on sodium, potassium and chloride concentrations in erythrocytes
of the malarious monkey. Am. J. Physiol. 152, 113–121.
Pavlovic-Djuranovic, S., Kun, J. F., Schultz, J. E., and Beitz, E. (2006). Dihydroxy-
acetone and methylglyoxal as permeants of the Plasmodium aquaglyceroporin
inhibit parasite proliferation. Biochim. Biophys. Acta 1758, 1012–1017. doi:
10.1016/j.bbamem.2005.12.002
Pillai, A. D., Addo, R., Sharma, P., Nguitragool, W., Srinivasan, P., and Desai,
S. A. (2013). Malaria parasites tolerate a broad range of ionic environments
and do not require host cation remodeling. Mol. Microbiol. 88, 20–34. doi:
10.1111/mmi.12159
Pillai, A. D., Nguitragool,W., Lyko, B., Dolinta, K., Butler,M.M., Nguyen, S. T., et al.
(2012). Solute restriction reveals an essential role for clag3-associated channels
in malaria parasite nutrient acquisition. Mol. Pharmacol. 82, 1104–1114. doi:
10.1124/mol.112.081224
Pillai, A. D., Pain, M., Solomon, T., Bokhari, A. A., and Desai, S. A.
(2010). A cell-based high-throughput screen validates the plasmodial surface
anion channel as an antimalarial target. Mol. Pharmacol. 77, 724–733. doi:
10.1124/mol.109.062711
Rager, N., Mamoun, C. B., Carter, N. S., Goldberg, D. E., and Ullman, B.
(2001). Localization of the Plasmodium falciparum PfNT1 nucleoside trans-
porter to the parasite plasma membrane. J. Biol. Chem. 276, 41095–41099. doi:
10.1074/jbc.M107037200
Sa, J. M., Twu, O., Hayton, K., Reyes, S., Fay, M. P., Ringwald, P., et al. (2009).
Geographic patterns of Plasmodium falciparum drug resistance distinguished
by differential responses to amodiaquine and chloroquine. Proc. Natl. Acad. Sci.
U.S.A. 106, 18883–18889. doi: 10.1073/pnas.0911317106
Saxena, M., and Henderson, G. B. (1996). MOAT4, a novel multispecific organic-
anion transporter for glucuronides and mercapturates in mouse L1210 cells and
human erythrocytes. Biochem. J. 320, 273–281.
Schwab, J. C., Beckers, C. J., and Joiner, K. A. (1994). The parasitophorous vacuole
membrane surrounding intracellular Toxoplasma gondii functions as a molec-
ular sieve. Proc. Natl. Acad. Sci. U.S.A. 91, 509–513. doi: 10.1073/pnas.91.2.
509
Sharma, P., Wollenberg, K., Sellers, M., Zainabadi, K., Galinsky, K., Moss, E.,
et al. (2013). An epigenetic antimalarial resistance mechanism involving par-
asite genes linked to nutrient uptake. J. Biol. Chem. 288, 19429–19440. doi:
10.1074/jbc.M113.468371
Simon, S. M., and Blobel, G. (1991). A protein-conducting channel in the endoplas-
mic reticulum. Cell 65, 371–380. doi: 10.1016/0092-8674(91)90455-8
Simon, S. M., and Blobel, G. (1992). Signal peptides open protein-conducting
channels in E. coli. Cell 69, 677–684. doi: 10.1016/0092-8674(92)90231-Z
Sparr, C., Purkayastha, N., Kolesinska, B., Gengenbacher, M., Amulic, B.,
Matuschewski, K., et al. (2013). Improved efficacy of fosmidomycin against Plas-
modium and Mycobacterium species by combination with the cell-penetrating
peptide octaarginine. Antimicrob. Agents Chemother. 57, 4689–4698. doi:
10.1128/AAC.00427-13
Staines, H. M., Alkhalil, A., Allen, R. J., De Jonge, H. R., Derbyshire, E., Egee, S., et
al. (2007). Electrophysiological studies ofmalaria parasite-infected erythrocytes:
current status. Int. J. Parasitol. 37, 475–482. doi: 10.1016/j.ijpara.2006.12.013
Stead, A. M., Bray, P. G., Edwards, I. G., DeKoning, H. P., Elford, B. C., Stocks,
P. A., et al. (2001). Diamidine compounds: selective uptake and targeting in
Plasmodium falciparum.Mol. Pharmacol. 59, 1298–1306.
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., et al. (2010).
Coexistence of passive and carrier-mediated processes in drug transport. Nat.
Rev. Drug Discov. 9, 597–614. doi: 10.1038/nrd3187
Vale, N., Moreira, R., and Gomes, P. (2009). Primaquine revisited six decades after
its discovery. Eur. J. Med. Chem. 44, 937–953. doi: 10.1016/j.ejmech.2008.08.011
van Breemen, R. B., and Li, Y. (2005). Caco-2 cell permeability assays to mea-
sure drug absorption. Expert. Opin. Drug Metab. Toxicol. 1, 175–185. doi:
10.1517/17425255.1.2.175
Visser, B. J., van, Vugt M., and Grobusch, M. P. (2014). Malaria: an update
on current chemotherapy. Expert. Opin. Pharmacother. 15, 2219–2254. doi:
10.1517/14656566.2014.944499
Vyas, N., Avery, B. A., Avery, M. A., and Wyandt, C. M. (2002). Carrier-mediated
partitioning of artemisinin into Plasmodium falciparum-infected erythro-
cytes. Antimicrob. Agents Chemother. 46, 105–109. doi: 10.1128/AAC.46.1.105-
109.2002
Wahajuddin, Raju, K. S., Singh, S. P., and Taneja, I. (2014). Investigation of the func-
tional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine.
Antimicrob. Agents Chemother. 58, 489–494. doi: 10.1128/AAC.01382-13
White, N. J. (2008). How antimalarial drug resistance affects post-treatment pro-
phylaxis.Malar. J. 7, 9. doi: 10.1186/1475-2875-7-9
Woodrow, C. J., Penny, J. I., and Krishna, S. (1999). Intraerythrocytic Plasmodium
falciparum expresses a high affinity facilitative hexose transporter. J. Biol. Chem.
274, 7272–7277. doi: 10.1074/jbc.274.11.7272
Frontiers in Pharmacology | www.frontiersin.org May 2015 | Volume 6 | Article 916
Basore et al. Antimalarial drug uptake by infected erythrocytes
Yan, A., Wang, Z., and Cai, Z. (2008). Prediction of human intestinal absorption by
GA feature selection and support vector machine regression. Int. J. Mol. Sci. 9,
1961–1976. doi: 10.3390/ijms9101961
Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., Kamchonwong-
paisan, S., Charman, S. A., et al. (2012). Malarial dihydrofolate reductase as a
paradigm for drug development against a resistance-compromised target. Proc.
Natl. Acad. Sci. U. S. A. 109, 16823–16828. doi: 10.1073/pnas.1204556109
Zeuthen, T., Wu, B., Pavlovic-Djuranovic, S., Holm, L. M., Uzcategui, N. L.,
Duszenko, M., et al. (2006). Ammonia permeability of the aquaglyceroporins
from Plasmodium falciparum, Toxoplasma gondii, and Trypanosoma
brucei. Mol. Microbiol. 61, 1598–1608. doi: 10.1111/j.1365-2958.2006.
05325.x
Zhao, Y. H., Abraham, M. H., Le, J., Hersey, A., Luscombe, C. N., Beck, G., et al.
(2002). Rate-limited steps of human oral absorption and QSAR studies. Pharm.
Res. 19, 1446–1457. doi: 10.1023/A:1020444330011
Zipprer, E. M., Neggers, M., Kushwaha, A., Rayavara, K., and Desai, S. A. (2014).
A kinetic fluorescence assay reveals unusual features of Ca++ uptake in Plas-
modium falciparum-infected erythrocytes.Malar. J. 13, 184. doi: 10.1186/1475-
2875-13-184
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Basore, Cheng, Kushwaha, Nguyen and Desai. This is an open-
access article distributed under the terms of the Creative CommonsAttribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org May 2015 | Volume 6 | Article 917
